Johnson & Johnson is paying a premium for lung-drug specialist Actelion -- and that's putting it mildly.
News & Analysis: ACTELION LTD
One of Actelion's lead drugs just stumbled in a phase 3 label expansion study. Why would J&J still go through with a buyout?
Did this proposed deal get even worse for J&J shareholders?
J&J's on again, off again pursuit of Actelion is back on.
Walking away from Actelion could prove to be a very smart move for Johnson & Johnson.
While attempting to offset biosimilar competition on their best-selling drugs, J&J and Sanofi could be making a big mistake by chasing Actelion.
This is a big risk this analyst believes J&J shouldn't be taking.